GlassScriptPhysician profile
Marc Alan Simon
NPI 1346215449
$114,392.18
in general payments reported to CMS, 2019-2025
21 companies · $24K in 2025
The $24K reported for 2025 was more than what 85% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $1,981 · 2021: $1,317 · 2022: $20K · 2023: $15K · 2024: $21K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Travel and Lodging: $8,623 · Food and Beverage: $7,172 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,058.00 |
| Travel and Lodging | $8,622.99 |
| Food and Beverage | $7,172.37 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $33,755.80 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $30,647.45 | 2022-2025 | Winrevair |
| United Therapeutics Corporation | $20,061.52 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals, LTD | $15,120.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11,238.30 | 2022-2025 | |
| Chiesi USA, INC. | $959.65 | 2025 | |
| Sandoz INC. | $579.28 | 2019-2025 | Treprostinil |
| Amgen INC. | $454.13 | 2019 | |
| Impulse Dynamics (USA) INC. | $440.30 | 2021 | |
| Kerecis Limited | $326.53 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Abbott Laboratories | $291.35 | 2023 | Cardiomems, 2nd Gen Centrimag Primary Console |
| Johnson & Johnson Health Care Systems INC. | $185.33 | 2022 | |
| Edwards Lifesciences Corporation | $175.25 | 2023 | Mitris Resilia Mitral Valve |
| Liquidia Technologies, INC. | $87.23 | 2025 | Yutrepia |
| Novartis Pharmaceuticals Corporation | $22.86 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $20.64 | 2022 | |
| Novo Nordisk INC | $15.54 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $10.44 | 2023 | Xarelto |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.